"The
Report Duchenne Muscular Dystrophy - Pipeline Review, H1 2017
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Summary
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1
2017, provides an overview of the Duchenne Muscular Dystrophy
(Genetic Disorders) pipeline landscape.
Duchenne
muscular dystrophy is a condition which causes muscle weakness. DMD
is an X-linked disorder. The gene for DMD is present on the X
chromosome. It codes for a protein named dystrophin. Dystrophin is
essential for providing structural support inside muscle cells.
Symptoms usually appear before age 6 and may appear as early as
infancy. They include fatigue, learning difficulties, intellectual
disability, muscle weakness and progressive difficulty walking.
View
Report @
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Duchenne Muscular Dystrophy - Pipeline Review, H1 2017, provides
comprehensive information on the therapeutics under development for
Duchenne Muscular Dystrophy (Genetic Disorders), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide
covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and
press releases.
The
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also
reviews of key players involved in therapeutic development for
Duchenne Muscular Dystrophy and features dormant and discontinued
projects. The guide covers therapeutics under Development by
Companies /Universities /Institutes, the molecules developed by
Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA
Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 7, 2,
51, 12 and 1 respectively. Similarly, the Universities portfolio in
Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 8
and 1 molecules, respectively.
Duchenne
Muscular Dystrophy (Genetic Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide
is built using data and information sourced from Global Markets
Directs proprietary databases, company/university websites, clinical
trial registries, conferences, SEC filings, investor presentations
and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are
captured on a real time basis.
Get
Sample Copy Of This Report @
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
-
The pipeline guide reviews pipeline therapeutics for Duchenne
Muscular Dystrophy (Genetic Disorders) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Duchenne
Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all
their major and minor projects.
-
The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic
Disorders) therapeutics based on mechanism of action (MoA), drug
target, route of administration (RoA) and molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-
The pipeline guide reviews latest news related to pipeline
therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Duchenne Muscular Dystrophy (Genetic Disorders).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and
focus of Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 5
Duchenne Muscular Dystrophy -
Overview 6
Duchenne Muscular Dystrophy -
Therapeutics Development 7
Duchenne Muscular Dystrophy -
Therapeutics Assessment 19
Duchenne Muscular Dystrophy -
Companies Involved in Therapeutics Development 29
Duchenne Muscular Dystrophy -
Drug Profiles 52
Duchenne Muscular Dystrophy -
Dormant Projects 248
Duchenne Muscular Dystrophy -
Discontinued Products 251
Duchenne Muscular Dystrophy -
Product Development Milestones 252
Appendix 263
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment